Search

Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening tool, supported by an ERC Proof of Concept Grant.

From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research.

There are few pregnancy diseases as life-threatening as preeclampsia. But the danger doesn’t end after birth: Mothers with preeclamptic pregnancies have a much higher risk of developing cardiovascular disease later in life. Kristin Kräker from the Experimental and Clinical Research Center is working on an early warning system.

The Berlin biotech Glycotope and the Max Delbrück Center have signed an agreement to explore the potential of combining Glycotope’s tumor-specific antibodies with CAR technology developed by the Max Delbrück Center. Their common goal: advancing immunotherapies against solid tumors.

After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse want to use novel CAR T-cell therapies to help patients with cancers that are currently untreatable.

The UNIPRENEURS Initiative has recognized the entrepreneurial spirit of 20 professors, among them ECRC researcher Simone Spuler. As a co-founder of the startup MyoPax, she is pioneering stem cell technology to develop regenerative therapies for previously incurable muscle diseases.

The stem cell therapy developed by MyoPax, a spin-off from the Max Delbrück Center and Charité, could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process. The necessary clinical trial will start in the fall.

While CAR-T cells have proven successful in treating certain types of leukemia and lymphoma, these immunotherapies can become even more effective. A clinical trial run by Charité and the Max Delbrück Center has been awarded a grant of several million euros to test a new approach.

Employees of the Max Delbrück Center and the Experimental and Clinical Research Center are mourning the loss of Gisela Krebs, who has passed away at the age of 91. Since 2015, her foundation has been supporting muscle desease research.

MyoPax develops regenerative therapies for previously incurable muscle diseases. An interview with co-founders Prof. Simone Spuler and Dr. Verena Schöwel-Wolf, now board member and CEO respectively